Zeke Capital Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History

Zeke Capital Advisors’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	$3.03M	Sell	12,770 -1,524	-11%	-$325K	0.2%	51
2022 Q3	$2.86M	Hold	14,294	–	–	0.21%	53
2022 Q2	$2.08M	Sell	14,294 -1,339	-9%	-$190K	0.14%	74
2022 Q1	$2.55M	Buy	15,633 +1,278	+9%	+$195K	0.13%	76
2021 Q4	$2.43M	Buy	14,355 +1,274	+10%	+$237K	0.14%	50
2021 Q3	$2.47M	Hold	13,081	–	–	0.14%	54
2021 Q2	$2.22M	Buy	+13,081	New	+$1.92M	0.14%	62
2020 Q1	–	Sell	-5,309	Closed	-$611K	–	247
2019 Q4	$611K	Sell	5,309 -1,261	-19%	-$126K	0.05%	335
2019 Q3	$528K	Sell	6,570 -1,438	-18%	-$114K	0.05%	347
2019 Q2	$581K	Buy	8,008 +733	+10%	+$56.2K	0.05%	321
2019 Q1	$680K	Sell	7,275 -2,429	-25%	-$203K	0.06%	285
2018 Q4	$708K	Buy	9,704 +2,351	+32%	+$181K	0.07%	262
2018 Q3	$644K	Buy	+7,353	New	+$740K	0.05%	341

Other funds holding ALNY

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Zeke Capital Advisors's ALNY Position: Q4 2022 in Review

Zeke Capital Advisors reduced its Alnylam Pharmaceuticals (ALNY) stake by 11% in Q4 2022, selling an estimated $325K and leaving 12,770 shares worth $3.03M. The position accounts for 0.2% of the portfolio, ranked #51.

Zeke Capital Advisors first reported a position in ALNY in Q3 2018 and has held it in 13 quarters since. 488 funds tracked by Wall St. Rank hold ALNY as of Q4 2022.

Zeke Capital Advisors held 12,770 shares of Alnylam Pharmaceuticals worth $3.03M as of Q4 2022.
Zeke Capital Advisors sold 1,524 Alnylam Pharmaceuticals shares in Q4 2022, an estimated $325K.
Alnylam Pharmaceuticals made up 0.2% of Zeke Capital Advisors's portfolio in Q4 2022, its #51 holding.
Zeke Capital Advisors first reported a position in Alnylam Pharmaceuticals in Q3 2018 and has held it in 13 quarters since.
488 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2022.

Based on Zeke Capital Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.